GB-5267 / Generate Biomedicines, Roswell Park - LARVOL DELTA

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Roswell Park Cancer Institute | Trial completion date: Jan 2030 ➔ Aug 2030 | Trial primary completion date: Jan 2028 ➔ Aug 2028

Platinum resistant • Trial completion date • Trial primary completion date • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Roswell Park Cancer Institute | Not yet recruiting ➔ Recruiting

Enrollment open • Platinum resistant • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

Recent Progress (PRNewswire) - "In oncology, Generate's GB-4362 (MMAE neutralizer) program has activated clinical trial sites, and the first patient is expected to be dosed in mid-2026...Generate's GB-5267 (MUC16 armored CAR T) program, developed in collaboration with Roswell Park Comprehensive Cancer Center, is expected to dose the first patient in the second half of 2026 in a Phase 1 clinical trial in solid tumors, initially targeting ovarian cancer."

Platinum resistant • Trial status • Ovarian Cancer • Urothelial Cancer

GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - P1 | N=18 | Not yet recruiting | Sponsor: Roswell Park Cancer Institute

New P1 trial • Platinum resistant • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Solid Tumor • MUC16

The biotech estimates $15 million of the proceeds will be needed to take GB-4362 and GB-5267 into the clinic. (FierceBiotech)

Financing • Solid Tumor